Excelent article with CYDY
Post# of 148278
(Total Views: 383)
Posted On: 12/17/2019 3:22:01 PM
CYDY posted as a competiror for GILD and MRK in light of USA anti HIV policies.
Excellent depiction of our Leronlimab.
https://seekingalpha.com/article/4312978-poli...ll-fumbled
"Next Generation Entry/Fusion Inhibitor - Non Toxic
CytoDyn Inc. (OTCQB:CYDY) has developed a monoclonal antibody CCR5 antagonist called leronlimab to treat HIV with virtually no side effects compared to the nausea, fatigue, and trouble sleeping that come with the HAART regimen. The drug has an impressive safety and efficacy profile. After 24 weeks of leronlimab therapy, 81% of patients had suppressed viral load compared to 43% from the last drug approved in the study's patient population. There were no drug-related Serious Adverse Events (SAEs), giving it one of the best safety profiles in the HIV landscape . Leronlimab also addresses patient compliance as a once-a-week injectable with a 72 hour grace period. The drug also has a fast-track designation and a rolling BLA and is in a position to ask for accelerated approval. It hit its primary endpoint in a pivotal phase 3 trial. They have a very favorable label request with one drug resistance in 3 classes or one drug resistance in 2 classes with limited treatment options. Approval could represent a$1.7 to $3.4 billion market within the first year of approval based on Biovid's Market Research. After expected approval, they plan to do a label expansion to switch to monotherapy maintenance."
We are gaining recognition !!!!. Is not any more:" too good to be true".
Excellent depiction of our Leronlimab.
https://seekingalpha.com/article/4312978-poli...ll-fumbled
Quote:
but this year, a new player with disruptive technology might be in the works.
"Next Generation Entry/Fusion Inhibitor - Non Toxic
CytoDyn Inc. (OTCQB:CYDY) has developed a monoclonal antibody CCR5 antagonist called leronlimab to treat HIV with virtually no side effects compared to the nausea, fatigue, and trouble sleeping that come with the HAART regimen. The drug has an impressive safety and efficacy profile. After 24 weeks of leronlimab therapy, 81% of patients had suppressed viral load compared to 43% from the last drug approved in the study's patient population. There were no drug-related Serious Adverse Events (SAEs), giving it one of the best safety profiles in the HIV landscape . Leronlimab also addresses patient compliance as a once-a-week injectable with a 72 hour grace period. The drug also has a fast-track designation and a rolling BLA and is in a position to ask for accelerated approval. It hit its primary endpoint in a pivotal phase 3 trial. They have a very favorable label request with one drug resistance in 3 classes or one drug resistance in 2 classes with limited treatment options. Approval could represent a$1.7 to $3.4 billion market within the first year of approval based on Biovid's Market Research. After expected approval, they plan to do a label expansion to switch to monotherapy maintenance."
We are gaining recognition !!!!. Is not any more:" too good to be true".
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼